Treatment with CNCs mitigates the severity of NASH by reducing expression of genes associated with the uptake of free fatty acids (CD36), liver inflammation (HMGB–1) and fibrosis (α–SMA). Here, ACTA1 is linked to metabolic dysfunction-associated steatohepatitis.